Abstract

Long‐term outcome of chronic myeloid leukaemia patients with p210 and p190 co‐expression at baseline

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients
Fabio Stagno ... Enrica Morra
American Journal of Hematology | VOL. 85
Fabio Stagno, et. al.Fabio Stagno ... Enrica Morra
10 Nov 2010
Imatinib for Chronic Myeloid Leukemia Patients: A Single Institution Experience
Ahmet Emre Eskazan ... Ayse Salihoglu
Blood | VOL. 118
Ahmet Emre Eskazan, et. al.Ahmet Emre Eskazan ... Ayse Salihoglu
18 Nov 2011
Chronic Myeloid Leukemia (CML) Patients with “Suboptimal” Response to Imatinib (IM) According to European LeukemiaNet Criteria Have a Poorer Outcome with Respect to “Optimal” Responders: A GIMEMA CML WORKING PARTY Analysis.
Tamara Intermesoli ... Bruno Martino
Blood | VOL. 114
Tamara Intermesoli, et. al.Tamara Intermesoli ... Bruno Martino
20 Nov 2009
Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.
Massimo Breccia ... Daniela Diverio
American journal of hematology | VOL. 90
Massimo Breccia, et. al.Massimo Breccia ... Daniela Diverio
30 Mar 2015
View more papers

More From: British Journal of Haematology

Paper Title
Journal
Date
Author
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Tamer Othman ... Ibrahim Aldoss
British journal of haematology | VOL. -
Tamer Othman, et. al.Tamer Othman ... Ibrahim Aldoss
29 May 2024
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group.
Herbert Pichler ... Adriana Balduzzi
British journal of haematology | VOL. -
Herbert Pichler, et. al.Herbert Pichler ... Adriana Balduzzi
27 May 2024
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
Douglas A Stewart ... Michael Crump
British journal of haematology | VOL. -
Douglas A Stewart, et. al.Douglas A Stewart ... Michael Crump
27 May 2024
RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
Siyang Wang ... Kankan Wang
British journal of haematology | VOL. -
Siyang Wang, et. al.Siyang Wang ... Kankan Wang
27 May 2024
View more papers